2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli B, Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology 2022, 7: 747-759. PMID: 35648414, DOI: 10.1001/jamacardio.2022.1292.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsRandomized clinical trialsAcute VTE treatmentDose adjustmentOral anticoagulantsLow-intensity treatmentPrimary preventionLarge registriesVTE treatmentHigh-risk medical patientsStable atherosclerotic vascular diseaseHigh-risk cancer patientsLarge randomized clinical trialsSecondary VTE preventionPeripheral artery diseaseAtherosclerotic vascular diseaseDaily clinical practiceRoutine practice patternEvidence of safetyRecent revascularizationStroke preventionVTE preventionArtery diseaseMedical patientsCancer patients
2006
Influenza Vaccination as Secondary Prevention for Cardiovascular Disease
Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM. Influenza Vaccination as Secondary Prevention for Cardiovascular Disease. Circulation 2006, 114: 1549-1553. PMID: 16982936, DOI: 10.1161/circulationaha.106.178242.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseSecondary preventionCardiovascular conditionsInfluenza vaccination coverage levelsInfluenza vaccination coverage ratesComprehensive secondary preventionAtherosclerotic vascular diseaseVaccination coverage ratesRandomized clinical trialsAmerican Heart AssociationVaccination coverage levelsCardiovascular morbidityCause mortalityInfluenza immunizationInfluenza vaccinationCohort studyInfluenza seasonInfluenza vaccineHeart AssociationAnnual vaccinationVascular diseaseClinical trialsAmerican CollegeCardiology practiceAttenuated vaccinesInfluenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology
Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM. Influenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology. Journal Of The American College Of Cardiology 2006, 48: 1498-1502. PMID: 17010820, DOI: 10.1016/j.jacc.2006.09.004.Peer-Reviewed Original ResearchConceptsSecondary preventionCardiovascular diseaseCardiovascular conditionsAmerican CollegeAmerican Heart Association/American CollegeInfluenza vaccination coverage levelsInfluenza vaccination coverage ratesComprehensive secondary preventionAtherosclerotic vascular diseaseVaccination coverage ratesRandomized clinical trialsAmerican Heart AssociationVaccination coverage levelsCardiovascular morbidityCause mortalityInfluenza immunizationInfluenza vaccinationCohort studyInfluenza seasonInfluenza vaccineScience AdvisoryHeart AssociationAnnual vaccinationVascular diseaseClinical trials